Sokal J E, Carpenter N, Nizet C
Boll Ist Sieroter Milan. 1978 Jul 31;57(3):294-305.
A total of 88 better risk patients and 47 poor-risk patients with chronic myeloid leukemia have received repeated vaccinations with BCG or BCG-cultured cell mixtures at our institutions. The number of viable BCG organisms injected appeared to be the most important parameter of immunologic stimulation in this study. Excessive doses of BCG were associated with a significant incidence of disabling complications and with no survival benefit. Better risk patients receiving lower doses of BCG had suggestive prolongation of survival (p less than 0.1). Immunotherapy had little effect on the course of poor-risk patients but evaluation of this heterogeneous population is difficult; additional studies would be desirable among patients in whom reversal of poor prognostic signs can be achieved.
在我们机构中，共有88例低危慢性髓系白血病患者和47例高危患者接受了卡介苗（BCG）或卡介苗培养细胞混合物的重复接种。在本研究中，注射的活卡介苗生物体数量似乎是免疫刺激的最重要参数。过量的卡介苗剂量与致残并发症的高发生率相关，且无生存获益。接受较低剂量卡介苗的低危患者生存期有延长的迹象（p<0.1）。免疫疗法对高危患者的病程影响不大，但评估这一异质性人群较为困难；对于能够实现不良预后体征逆转的患者，有必要开展更多研究。
